These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 3053124)

  • 21. Drugs for treatment of peptic ulcers.
    Dajani EZ; Trotman BW
    J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.
    Vantrappen G; Schuurmans P; Rutgeerts P; Janssens J
    Scand J Gastroenterol Suppl; 1982; 80():23-30. PubMed ID: 6761849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The actions of bismuth in the treatment of Helicobacter pylori infection.
    Lambert JR; Midolo P
    Aliment Pharmacol Ther; 1997 Apr; 11 Suppl 1():27-33. PubMed ID: 9146788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug therapy for peptic ulcer: drugs that act on the gastric mucosa.
    Kauffman GL
    J Clin Gastroenterol; 1981; 3(Suppl 2):95-101. PubMed ID: 6119340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
    Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
    Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
    Bardhan KD; Singh S; Morris P; Thompson M; Hinchliffe RF; Cary BA; Wall RM; Blakemore CB
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):128-34. PubMed ID: 9646192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
    Eberhardt R; Kasper G
    Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats.
    Konturek SJ; Dembinski A; Warzecha Z; Bielanski W; Brzozowski T; Drozdowicz D
    Gut; 1988 Jul; 29(7):894-902. PubMed ID: 3260885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of colloidal bismuth subcitrate in gastric ulcer and gastritis.
    Tytgat GN; Rauws E; Langenberg W
    Scand J Gastroenterol Suppl; 1986; 122():22-9. PubMed ID: 3535018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers.
    Ward M; Halliday C; Cowen AE
    Digestion; 1986; 34(3):173-7. PubMed ID: 3530861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease.
    Sarosiek J; Bilski J; Murty VL; Slomiany A; Slomiany BL
    Am J Gastroenterol; 1989 May; 84(5):506-10. PubMed ID: 2470250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newer drugs in the treatment of peptic ulcer.
    Tandon BN
    Trop Gastroenterol; 1985; 6(4):188-92. PubMed ID: 3913076
    [No Abstract]   [Full Text] [Related]  

  • 37. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing.
    McLean AJ; Harcourt DM; McCarthy PG; Dudley FJ; McNeil JJ
    Med J Aust; 1987 Apr; 146(8):431-3, 436-8, 442. PubMed ID: 2886896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.